Cooper Companies, Inc. (The) (NYSE:COO)‘s stock had its “hold” rating reissued by analysts at Oppenheimer Holdings, Inc. in a note issued to investors on Tuesday. They currently have a $250.00 price target on the medical device company’s stock. Oppenheimer Holdings, Inc.’s target price suggests a potential upside of 1.38% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. Robert W. Baird reissued a “buy” rating and issued a $273.00 target price on shares of Cooper Companies, Inc. (The) in a research note on Tuesday. J P Morgan Chase & Co reissued a “hold” rating and issued a $235.00 target price on shares of Cooper Companies, Inc. (The) in a research note on Tuesday. Stifel Nicolaus raised their target price on shares of Cooper Companies, Inc. (The) from $265.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research raised shares of Cooper Companies, Inc. (The) from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research note on Friday, September 8th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $272.00 target price on shares of Cooper Companies, Inc. (The) in a research note on Friday, September 1st. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $257.60.

Cooper Companies, Inc. (NYSE COO) opened at 246.60 on Tuesday. Cooper Companies, Inc. has a 52 week low of $158.73 and a 52 week high of $256.39. The firm has a market capitalization of $12.05 billion, a price-to-earnings ratio of 36.97 and a beta of 0.59. The stock’s 50 day moving average is $245.39 and its 200-day moving average is $223.93.

Cooper Companies, Inc. (The) (NYSE:COO) last announced its earnings results on Thursday, August 31st. The medical device company reported $2.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.58 by $0.06. Cooper Companies, Inc. (The) had a net margin of 16.45% and a return on equity of 16.00%. The firm had revenue of $556.00 million for the quarter, compared to analyst estimates of $552.32 million. During the same quarter last year, the business earned $2.30 earnings per share. Cooper Companies, Inc. (The)’s revenue was up 8.0% compared to the same quarter last year. On average, equities research analysts expect that Cooper Companies, Inc. will post $9.72 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/14/cooper-companies-inc-the-coo-rating-reiterated-by-oppenheimer-holdings-inc.html.

In other news, CEO Paul L. Remmell sold 9,294 shares of Cooper Companies, Inc. (The) stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $248.46, for a total value of $2,309,187.24. Following the completion of the transaction, the chief executive officer now directly owns 6,186 shares of the company’s stock, valued at approximately $1,536,973.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Daniel G. Mcbride sold 6,000 shares of Cooper Companies, Inc. (The) stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $244.23, for a total transaction of $1,465,380.00. Following the completion of the transaction, the chief operating officer now directly owns 34,395 shares of the company’s stock, valued at $8,400,290.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,015 shares of company stock valued at $4,193,502. 1.60% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of COO. Capstone Asset Management Co. bought a new stake in Cooper Companies, Inc. (The) in the 1st quarter valued at about $269,000. Profund Advisors LLC raised its position in shares of Cooper Companies, Inc. (The) by 9.1% during the 1st quarter. Profund Advisors LLC now owns 2,059 shares of the medical device company’s stock worth $412,000 after buying an additional 171 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Cooper Companies, Inc. (The) by 1.5% during the 1st quarter. ProShare Advisors LLC now owns 4,896 shares of the medical device company’s stock worth $979,000 after buying an additional 73 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Cooper Companies, Inc. (The) by 33.7% during the 1st quarter. Wells Fargo & Company MN now owns 152,303 shares of the medical device company’s stock worth $30,443,000 after buying an additional 38,379 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI bought a new stake in shares of Cooper Companies, Inc. (The) during the 1st quarter worth about $237,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

About Cooper Companies, Inc. (The)

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Stock Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related stocks with our FREE daily email newsletter.